Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above 50 Day Moving Average – Time to Sell?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)’s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $46.43 and traded as high as $55.72. Xenon Pharmaceuticals shares last traded at $54.48, with a volume of 966,676 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. HC Wainwright upped their target price on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Guggenheim reaffirmed a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Bank of America reissued a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Stifel Nicolaus set a $66.00 price objective on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $71.88.

Xenon Pharmaceuticals Trading Down 1.9%

The company has a 50-day simple moving average of $46.43 and a 200 day simple moving average of $43.07. The company has a market cap of $4.53 billion, a P/E ratio of -12.50 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period last year, the company posted ($0.84) earnings per share. On average, equities analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In related news, insider Andrea Difabio sold 1,342 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $74,118.66. Following the completion of the sale, the insider owned 7,301 shares in the company, valued at approximately $403,234.23. The trade was a 15.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher John Kenney sold 1,410 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the transaction, the insider directly owned 7,069 shares in the company, valued at approximately $390,420.87. This trade represents a 16.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 336,707 shares of company stock worth $19,622,565 in the last 90 days. 4.07% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several institutional investors have recently made changes to their positions in XENE. Rockefeller Capital Management L.P. lifted its stake in Xenon Pharmaceuticals by 450.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 900 shares during the period. Corient Private Wealth LLC bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $1,125,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $55,000. Mackenzie Financial Corp bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $210,000. Finally, ADAR1 Capital Management LLC increased its holdings in Xenon Pharmaceuticals by 7.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock valued at $9,142,000 after buying an additional 14,871 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.